supported by the National Key R&D Plan of China(No.2022YFC3602904);the National Natural Science Foundation of China(Nos.81974395,82173036);Guangdong Basic and Applied Basic Research Foundation(No.2019A1515011437);International Science and Technology Cooperation Project Plan of Guangdong Province(No.2021A0505030085);Sun Yat-Sen University Clinical Research 5010 Program(No.2019005);Beijing Bethune Charitable Foundation(No.mnzl202001);Guangzhou Science and Technology Key R&D Project(No.202206010117);Beijing CSCO Clinical Oncology Research Foundation(Nos.Ytongshu2021/ms-0162,Y-MSDZD2022-0760);Guangdong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation(No.2020B1212060018OF006);Guangdong Provincial Clinical Research Center for Urological Diseases(No.2020B1111170006);supported by the National Natural Science Foundation of China(Nos.52173150,51973243);supported by the National Natural Science Foundation of China(No.82173088);Natural Science Foundation of Guangdong(No.2022A1515012383);the Guangzhou Science and Technology Fund(No.A202201011299)
Traditional therapies such as surgery and endocrine therapy no longer meet the clinical needs in prostate cancer treatment,and more effective treatments are urgently required.Recent studies have reported that targeted...
supported by the National Key R&D Program of China(2021YFA0909900)。
The high incidence rates and complicated subtypes of prostate cancer(PCa)call for the demand of the precise diagnostic and therapeutic strategies.Current clinical imaging techniques,such as MRI,CT,and ultrasonography ...
Supported by the National Natural Science Foun-dation of China(Nos.81672550,81974395);Guangdong Basic and Applied Basic Research Foundation(No.2019A1515011437);In-ternational Science and Technology Cooperation Project Plan of Guangdong Province(No.2021A0505030085);Sun Yat-sen Uni-versity Clinical Research 5010 Program(No.2019005);Sun Yat-sen Clinical Research Cultivating Program(No.201702);Guang-dong Province Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation(No.2020B1212060018OF006);Guangdong Provincial Clinical Research Center for Urological Diseases(No.2020B1111170006)to Hai Huang,the National Natural Science Foundation of China(No.51973243);Fundamental Research Funds for the Central Universities(No.191gzd35);International Coop-eration and Exchange of the National Natural Science Founda-tion of China(No.51820105004),Shenzhen Basic Research Project(No.JCYJ20190807155801657);the Project for Science&Technology New Star of Zhujiang in Guangzhou City(No.201906010082).
Prostate cancer(PCa)is the second most commonly diagnosed cancer in men.The Rac1-GTP inhibitor NSC23766 has been shown to suppress PCa growth.However,these therapies have low tumor-targeting efficacy in vivo.Therefore...
Supported by agrant from the Network Researches of Tumor Precise Radiation Therapy of Ministry of Health of China(No.WKJ2005-3-006)
Objective:Prostate cancer is a form of cancer that develops in the prostate,a gland in the male reproductive system.Prostate cancer tends to develop in men over the age of fifty;it is one of the most prevalent types o...